U.S./EU drug agency collaboration
This article was originally published in The Tan Sheet
Executive SummaryFDA and the European Medicines Agency extend their confidentiality arrangement related to medicinal products indefinitely "without the need for further renewal," EMA announces Sept. 15. The collaboration allows the agencies to exchange confidential information as part of their regulatory and scientific processes, including scientific advice and data on good manufacturing practice and good clinical practice inspection reports, marketing authorization procedures and post-marketing surveillance. The extension follows their initial deal signed in 2003
You may also be interested in...
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
Quanta Dialysis is linking up with B. Braun Avitum UK to support patients with Quanta’s personal hemodialysis device in the home. See what Quanta CEO John Milad said about it here.
Cosmetics Europe’s Director-General John Chave discusses next steps in the European Union’s proposed drive to ban manufactured microplastic in all cosmetic products. Industry continues to fight for something more proportionate, but it’s up against powerful forces in today’s European theater.